日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Accuracy of plasma biomarkers to detect Alzheimer's disease proteinopathy prior to dementia

血浆生物标志物在痴呆症发生前检测阿尔茨海默病蛋白病变的准确性

Cody, Karly A; Du, Lianlian; Studer, Rachel L; Jonaitis, Erin M; Asthana, Sanjay; Christian, Bradley T; Chin, Nathaniel A; Kirmess, Kris M; Meyer, Matthew R; Yarasheski, Kevin E; West, Tim; Verghese, Philip B; Braunstein, Joel B; Betthauser, Tobey J; Langhough, Rebecca E; Johnson, Sterling C

Independent validation of the PrecivityAD2(™) blood test to identify presence or absence of brain amyloid pathology in individuals with cognitive impairment

独立验证 PrecivityAD2™ 血液检测在识别认知障碍患者脑内淀粉样蛋白病理存在与否方面的有效性

Coppinger, Justine; West, Tim; Kirmess, Kris M; Fogelman, Ilana; Ray, Sutapa; Aurora, Sheena; Verghese, Philip B; Braunstein, Joel B; Yarasheski, Kevin E

Independent validation of the PrecivityAD2™ blood test to identify presence or absence of brain amyloid pathology in individuals with cognitive impairment

独立验证PrecivityAD2™血液检测在识别认知障碍患者脑内淀粉样蛋白病理存在与否方面的有效性

Coppinger, Justine; West, Tim; Kirmess, Kris M; Fogelman, Ilana; Ray, Sutapa; Verghese, Philip B; Braunstein, Joel B; Yarasheski, Kevin E

Clinical validation of the PrecivityAD2 blood test: A mass spectrometry-based test with algorithm combining %p-tau217 and Aβ42/40 ratio to identify presence of brain amyloid

PrecivityAD2血液检测的临床验证:一种基于质谱的检测方法,其算法结合了%p-tau217和Aβ42/40比值,用于识别脑淀粉样蛋白的存在。

Meyer, Matthew R; Kirmess, Kristopher M; Eastwood, Stephanie; Wente-Roth, Traci L; Irvin, Faith; Holubasch, Mary S; Venkatesh, Venky; Fogelman, Ilana; Monane, Mark; Hanna, Lucy; Rabinovici, Gil D; Siegel, Barry A; Whitmer, Rachel A; Apgar, Charles; Bateman, Randall J; Holtzman, David M; Irizarry, Michael; Verbel, David; Sachdev, Pallavi; Ito, Satoshi; Contois, John; Yarasheski, Kevin E; Braunstein, Joel B; Verghese, Philip B; West, Tim

Plasma Aβ42/Aβ40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease

血浆Aβ42/Aβ40和磷酸化tau217浓度比值可提高临床前阿尔茨海默病中淀粉样蛋白PET分类的准确性

Rissman, Robert A; Langford, Oliver; Raman, Rema; Donohue, Michael C; Abdel-Latif, Sara; Meyer, Matthew R; Wente-Roth, Traci; Kirmess, Kristopher M; Ngolab, Jennifer; Winston, Charisse N; Jimenez-Maggiora, Gustavo; Rafii, Michael S; Sachdev, Pallavi; West, Tim; Yarasheski, Kevin E; Braunstein, Joel B; Irizarry, Michael; Johnson, Keith A; Aisen, Paul S; Sperling, Reisa A

Associations of sleep duration and daytime sleepiness with plasma amyloid beta and cognitive performance in cognitively unimpaired, middle-aged and older African Americans

睡眠时长和日间嗜睡与血浆β-淀粉样蛋白和认知能力之间的关联,研究对象为认知功能正常的非裔美国人中年人和老年人

Cook, Jesse D; Malik, Ammara; Plante, David T; Norton, Derek; Langhough Koscik, Rebecca; Du, Lianlian; Bendlin, Barbara B; Kirmess, Kris M; Holubasch, Mary S; Meyer, Matthew R; Venkatesh, Venky; West, Tim; Verghese, Philip B; Yarasheski, Kevin E; Thomas, Kevin V; Carlsson, Cynthia M; Asthana, Sanjay; Johnson, Sterling C; Gleason, Carey E; Zuelsdorff, Megan

PrecivityAD2™ Blood Test: Analytical Validation of an LC-MS/MS Assay for Quantifying Plasma Phospho-tau217 and Non-Phospho-tau217 Peptide Concentrations That Are Used with Plasma Amyloid-β42/40 in a Multianalyte Assay with Algorithmic Analysis for Detecting Brain Amyloid Pathology

PrecivityAD2™ 血液检测:用于定量血浆中磷酸化 tau217 和非磷酸化 tau217 肽浓度的 LC-MS/MS 检测方法的分析验证,该方法与血浆淀粉样蛋白 β42/40 一起用于多分析物检测,并采用算法分析来检测脑淀粉样蛋白病理。

Eastwood, Stephanie M; Meyer, Matthew R; Kirmess, Kristopher M; Wente-Roth, Traci L; Irvin, Faith; Holubasch, Mary S; Verghese, Philip B; West, Tim; Braunstein, Joel B; Yarasheski, Kevin E; Contois, John H

The Association of Alzheimer's Disease-Related Blood-Based Biomarkers with Cognitive Screening Test Performance in the Congolese Population in Kinshasa

阿尔茨海默病相关血液生物标志物与金沙萨刚果人群认知筛查测试表现的关联性研究

Schwinne, Megan; Alonso, Alvaro; Roberts, Blaine R; Hickle, Sabrina; Verberk, Inge M W; Epenge, Emmanuel; Gikelekele, Guy; Tsengele, Nathan; Kavugho, Immaculee; Mampunza, Samuel; Yarasheski, Kevin E; Teunissen, Charlotte E; Stringer, Anthony; Levey, Allan; Ikanga, Jean

Protocol for a seamless phase 2A-phase 2B randomized double-blind placebo-controlled trial to evaluate the safety and efficacy of benfotiamine in patients with early Alzheimer's disease (BenfoTeam)

一项无缝衔接的 2A 期-2B 期随机双盲安慰剂对照试验方案,旨在评估苯磷硫胺在早期阿尔茨海默病患者中的安全性和有效性(BenfoTeam)

Feldman, Howard H; Luchsinger, José A; Léger, Gabriel C; Taylor, Curtis; Jacobs, Diane M; Salmon, David P; Edland, Steven D; Messer, Karen; Revta, Carolyn; Flowers, Sarah A; Jones, Kerry S; Koulman, Albert; Yarasheski, Kevin E; Verghese, Philip B; Venkatesh, Venky; Zetterberg, Henrik; Durant, January; Lupo, Jody-Lynn; Gibson, Gary E

Unexpected Low Rate of Amyloid-β Pathology in Multiple Sclerosis Patients

多发性硬化症患者中β-淀粉样蛋白病理发生率出乎意料地低

Brier, Matthew R; Schindler, Suzanne E; Salter, Amber; Perantie, Dana; Shelley, Nicole; Judge, Bradley; Keefe, Sarah; Kirmess, Kristopher M; Verghese, Philip B; Yarasheski, Kevin E; Venkatesh, Venky; Raji, Cyrus A; Gordon, Brian A; Bateman, Randall J; Morris, John C; Naismith, Robert T; Holtzman, David M; Benzinger, Tammie L S; Cross, Anne H